From: Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study
Risk group
HR (95% CI)
P
Intermediate risk vs. low risk
2.529 (1.120–5.707)
0.025
High risk vs. low risk
6.577 (3.419–12.655)
< 0.001